So we used a similar approach for alpha-synuclein. So again, using our computational modeling platform to model the misfolding of alpha-synuclein that gives rise to toxic species and what becomes exposed on these toxic forms of alpha-synuclein that we could vaccinate against. And once again, we found four dominant conformational epitopes, these little misfolded regions that are unique to toxic alpha-synuclein that can be a target for antibodies...
So we used a similar approach for alpha-synuclein. So again, using our computational modeling platform to model the misfolding of alpha-synuclein that gives rise to toxic species and what becomes exposed on these toxic forms of alpha-synuclein that we could vaccinate against. And once again, we found four dominant conformational epitopes, these little misfolded regions that are unique to toxic alpha-synuclein that can be a target for antibodies. And did mouse vaccination studies. And the antibodies that we induced by the vaccination were selective for toxic oligomers, no binding to monomers, no binding to Lewy bodies in the brains of Lewy body dementia patients. And so that’s what we wanted. And again, there’s many different combinations. So what are you going to put in a vaccine of these four? 15 possible combinations. And in this case, it was a combination of two of the epitopes that gave the maximal binding of high affinity antibodies binding toxic alpha-synuclein and brain homogenates from patients with Lewy body dementia. So that is what we chose as our clinical candidate for development to move forward, hopefully, into the clinic.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
